NCT04271163

Transcranial Electromagnetic Treatment (TEMT) Against Alzheimer's Disease

Status unknown Phase 1, PHASE2 Last updated 17 February 2020

What this trial tests

Phase 1, PHASE2 trial testing MemorEM in Alzheimer's Disease in 6 participants. Status unknown.

Timeline

10 February 2020

Primary endpoint
28 February 2021

31 March 2021

Quick facts

Lead sponsor	NeuroEM Therapeutics, Inc.
Phase	Phase 1, PHASE2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	6
Start date	10 February 2020
Primary completion	28 February 2021
Estimated completion	31 March 2021
Sites	1 location across United States

Drugs / interventions tested

• MemorEM

Conditions studied

• Alzheimer's Disease — all drugs for Alzheimer's Disease →

Sponsor

NeuroEM Therapeutics, Inc.

Who can join

63 and older, any sex, with Alzheimer's Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a second extension of EM 1000-1 wherein mild/moderate AD subjects who participated in the original study have completed participation in a first extension of 4-months. Most of the eight subjects in the original EM 1000-1 and first extension agreed to participate in this second extension study. The time between completion of the first extension and the second extension is 4 months. This second extension study;'s primary objective is to determine the long-term safety and efficacy of 12 months of daily treatment on performance of these AD subjects in the same comprehensive array of cognitive tasks as they performed in the initial 2-month study and 4-month first extension.Secondary objectives include analysis of blood for AD markers and evaluation of safety throughout the treatment period. Upon completion of this 12-month extension, the period between initial treatment and final treatment will be 2-3 years.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

1. Modulation of Brain Hyperexcitability: Potential New Therapeutic Approaches in Alzheimer's Disease.
   Toniolo S, Sen A, Husain M. · · 2020 · cited 74× · PMID 33297460 · DOI 10.3390/ijms21239318
2. Therapy for Alzheimer's disease: Missing targets and functional markers?
   Stoiljkovic M, Horvath TL, Hajós M. · · 2021 · cited 52× · PMID 33711510 · DOI 10.1016/j.arr.2021.101318
3. Transcranial Electromagnetic Treatment Stops Alzheimer's Disease Cognitive Decline over a 2½-Year Period: A Pilot Study.
   Arendash G, Abulaban H, Steen S, Andel R, et al · · 2022 · cited 13× · PMID 36005647 · DOI 10.3390/medicines9080042
4. Transcranial Electromagnetic Wave Treatment: A Fountain of Healthy Longevity?
   Arendash G, Cao C. · · 2023 · cited 6× · PMID 37298603 · DOI 10.3390/ijms24119652
5. The Brain Toxin Cleansing of Sleep Achieved During Wakefulness.
   Arendash GW. · · 2025 · cited 1× · PMID 39941597 · DOI 10.3390/jcm14030926
6. The Evidence That Brain Cancers Could Be Effectively Treated with In-Home Radiofrequency Waves.
   Arendash GW. · · 2025 · PMID 40867293 · DOI 10.3390/cancers17162665